Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model” by Hinz, Marty et al.
© 2011 Hinz et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2011:4 101–113
International Journal of Nephrology and Renovascular Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
101
RevIew
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJNRD.S22783
validity of urinary monoamine assay sales under 
the “spot baseline urinary neurotransmitter 
testing marketing model”
Marty Hinz1
Alvin Stein2
Thomas Uncini3
1Clinical Research, Neuro Research 
Clinics Inc, Cape Coral, FL; 2Stein 
Orthopedic Associates, Plantation,  
FL; 3Laboratory, Fairview Regional 
Medical Center-Mesabi, Hibbing, 
MN, USA
Correspondence: Marty Hinz 
1008 Dolphin Dr, Cape Coral,  
FL 33904, USA 
Tel +1 218 626 2220 
Fax +1 218 626 1638 
email marty@hinzmd.com
Abstract: Spot baseline urinary monoamine assays have been used in medicine for over 50 years 
as a screening test for monoamine-secreting tumors, such as pheochromocytoma and carcinoid 
syndrome. In these disease states, when the result of a spot baseline monoamine assay is above 
the specific value set by the laboratory, it is an indication to obtain a 24-hour urine sample to make 
a definitive diagnosis. There are no defined applications where spot baseline urinary monoamine 
assays can be used to diagnose disease or other states directly. No peer-reviewed published original 
research exists which demonstrates that these assays are valid in the treatment of individual patients 
in the clinical setting. Since 2001, urinary monoamine assay sales have been promoted for numer-
ous applications under the “spot baseline urinary neurotransmitter testing marketing model”. There 
is no published peer-reviewed original research that defines the scientific foundation upon which 
the claims for these assays are made. On the contrary, several articles have been published that 
discredit various aspects of the model. To fill the void, this manuscript is a comprehensive review 
of the scientific foundation and claims put forth by laboratories selling urinary monoamine assays 
under the spot baseline urinary neurotransmitter testing marketing model.
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Introduction
About 10 years ago, a laboratory began selling urinary monoamine assays under the 
“spot baseline urinary neurotransmitter testing marketing model”. It was claimed that 
these assays had a direct relationship with the levels of the monoamine neurotransmit-
ters in the brain and peripheral nervous system. The marketing model also made 
numerous previously unknown claims regarding medical applications of urinary 
monoamine assays. Attached to each monoamine assay report from the laboratory 
were recommendations for treating monoamine neurotransmitter-related diseases, 
such as depression and attention deficit hyperactivity disorder, using nutritional supple-
ments in conjunction with the testing. The recommended nutritional supplements in 
all cases were sold exclusively by those selling the laboratory assays.1–4 This medical 
treatment methodology continues to be marketed today by several laboratories, physi-
cians, other types of caregivers, and directly to the public over the Internet. In the 
process, the scope of urinary monoamine assay marketing claims has increased. 
This review examines the validity of this approach.
Without the benefit of published peer-reviewed research discussing or supporting 
the scientific foundation of the testing, many physicians and caregivers have joined 
  laboratories in expanding the Internet marketing campaign for this type of testing 
coupled with nutritional supplement sales.1–4International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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This manuscript reviews and discusses the validity of 
clinical applications promoted to enhance the sales of urinary 
serotonin, dopamine, norepinephrine, and/or epinephrine 
(herein referred to as “monoamine”) assays. The reference 
point for this discussion and review is ten peer-reviewed 
research papers relating to clinical applications of monoam-
ine assays published by the authors of this manuscript since 
2009 (as listed in Table 1).5–14
The topic is the rationale, validity, and clinical impact of 
marketing claims used to sell urinary monoamine assays 
under the “spot baseline urinary neurotransmitter testing 
marketing model”. It is the hypothesis of this manuscript that 
the “spot baseline urinary neurotransmitter testing model” 
is not a model based on science, but is a business marketing 
tool, and a model formulated to drive laboratory sales of 
urinary monoamine assays. There is no original research 
published in scientific journals that discusses or defines the 
scientific foundation of the model. It is hereby asserted that 
the foundation upon which the model rests is clinically 
unproven. The alleged scientific foundation put forth in 
promotional sales material under this marketing model con-
tradicts known science, especially in the areas of renal 
physiology and blood–brain barrier permeability.
There is no formal laboratory test known as the “urinary 
neurotransmitter testing”. From an objective scientific perspec-
tive, the proper nomenclature for the relevant laboratory testing 
is “urinary monoamine assays”. The monoamines, ie, serotonin, 
dopamine, norepinephrine, and epinephrine, do not function 
exclusively as neurotransmitters. They carry out other major 
neurotransmitter, neurohormonal, regulatory, autocrine, and 
paracrine functions. The monoamines found in the urine have 
not, do not, and will not function exclusively as   neurotransmitters. 
Therefore, it is not appropriate to refer to urinary monoamine 
assays as “neurotransmitter testing” and ignore the other major 
functions of these monoamines in the body.15
Urinary monoamines exist in one of two states. The 
“endogenous state” is the normal day-to-day state. This occurs 
when a subject is taking no amino acids. The “  competitive 
inhibition state” is found when significant amounts of both 
serotonin and dopamine amino acid precursors are being 
taken simultaneously.6,9–11,13 This clinical review is undertaken 
exclusively to discuss the testing performed in the endogenous 
state with spot baseline urine samples.
The following applications are direct quotes from a labo-
ratory website7 that is promoting some of the alleged attri-
butes of the spot baseline urinary neurotransmitter marketing 
testing model. These include, but are not limited to:
•	 “…. baseline (urinary neurotransmitter) testing is the best 
approach to determine the neurotransmitter functional 
status of the central and peripheral nervous systems”
•	 “Administration of amino acid precursors directly impacts 
urinary monoamine levels; therefore, the results of mono-
amine assays merely need to be interpreted as being either 
high or low values with no need to make consideration for 
other forces impacting urinary monoamine levels between 
renal synthesis and showing up in the final urine”
•	 “Baseline testing of urinary monoamines prior to starting 
supplemental amino acid precursors is required in order 
to define the amino acid precursor starting dose needed 
in treatment”
Table 1 Overview and summary of previous papers by the authors 
of this paper
Authors Comments
Hinz5 Use of serotonin and dopamine precursors guided 
by organic cation transporter optimization in the 
treatment of depression.
Trachte et al14 This is written by the chairman of the research 
committee, University of Minnesota Medical School, 
Duluth, MN, based on laboratory data provided by and 
in collaboration with Marty Hinz. The paper documents 
the response of urinary serotonin and dopamine to 
administration of L-tyrosine in a large group.
Hinz et al6 Publishing of a new organic cation transporter model 
relating to monoamine transport.
Hinz et al7 Discusses the validity of day to day reproducibility of 
spot baseline urinary serotonin and dopamine samples 
in the same subject. Findings were that testing differs 
significantly from day to day in the same subject and is 
not reproducible.
Hinz et al8 Differentiation of major affective disorder from 
depression-dominant bipolar disorder and treatment 
with serotonin and dopamine amino acid precursors, 
guided by transporter assay optimization.
Stein et al13 A treatment protocol for treatment of Crohn’s disease 
with amino acids guided by organic cation transporter 
functional status determination.
Hinz et al9 Treatment of attention deficit hyperactivity 
disorder with serotonin and dopamine amino acid 
precursors, guided by organic cation transporter assay 
optimization.
Hinz et al10 Discusses the validity of day to day reproducibility of 
spot baseline urinary norepinephrine and epinephrine 
samples in the same subject. Findings were that testing 
differs significantly from day to day in the same subject 
and is not reproducible.
Hinz et al11 Management of Parkinson disease with organic cation 
transporter optimization in a manner that allows for 
management and control of all problems associated 
directly and indirectly with L-dopa administration 
during treatment.
Hinz et al12 A paper written in response to an editor invitation. 
The paper reviews a paper titled, “Non-validity and 
clinical relevance of neurotransmitter testing”.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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•	 “Baseline (urinary) monoamine assays in the absence of 
supplemental amino acid precursors are required to diag-
nose and define the serotonin and dopamine imbalance 
in the central and peripheral nervous systems”
•	 “Baseline (urinary) monoamine assays can serve as a 
reference point to gauge treatment effectiveness after 
amino acid precursors are started”
•	 “Baseline (urinary) monoamine assays can be used to 
reduce the risk of side effects when amino acid precursor 
treatment is started”.
The “spot baseline urinary neurotransmitter testing mar-
keting model” (herein referred to as “the marketing model”) 
claims that the clinical applications for the test are based on 
science, yet when the alleged scientific claims supporting 
the marketing model are examined, they are contradicted by 
known science.
At present, the only clinically proven use for spot baseline 
urinary monoamine assays is as a screening test for pheo-
chromocytoma or carcinoid syndrome to determine if a 
24-hour urine test is needed to diagnose these diseases 
definitively. This application is hereby specifically excluded 
from consideration in this manuscript.
Physician marketing claims
Physicians and other caregivers are promoting sales of uri-
nary monoamine assays under the “spot baseline urinary 
neurotransmitter testing marketing model” on the Internet. 
It is easy to find this type of advertising. This section dis-
cusses how some physicians were induced to promote this 
marketing model. The section ends with examples of market-
ing claims by physicians and caregivers currently found on 
the Internet.
This “spot baseline urinary neurotransmitter testing 
marketing model” has become known as the “pee in a cup 
and we will determine the neurotransmitter levels in your 
brain model”. It is asserted that the alleged scientific state-
ments driving sales of urinary monoamine assays are decep-
tively simple and intuitively seductive.
The actual science required to support or contradict “the 
marketing model” is found primarily in the renal physiology 
literature and blood–brain barrier permeability. It is asserted 
that this area of monoamine renal physiology is extraordi-
narily complex, especially for the uninitiated.
Physicians have implicit trust that the laboratory is giving 
accurately reported results and advice. For most physicians, 
this trust is cultivated by a history of dealing with only 
  hospital and/or clinic-based laboratories under the medical 
direction of physicians who implement widely accepted 
treatment standards and testing policies. A basic flaw here 
is that the laboratories selling urinary monoamine assays 
under the “spot baseline urinary neurotransmitter testing 
marketing model” are not clinic-based or hospital-based. 
They are freestanding facilities directed and staffed by chem-
ists who have no medical training or medical license.16–18
These laboratories are claiming, in their marketing, to 
have the expertise to tell physicians how to treat their 
patients, on a broad level, on the basis of the laboratory 
studies they perform. These laboratories provide “technical 
support” to assist physicians in treating their patients. 
The quality of this technical support raises concerns. Routine 
technical support is given by individuals with no formal 
medical training, no first-hand experience in patient care, 
and no medical licensure. In some cases, individuals with 
only a high-school degree, who are trained only from a 
marketing standpoint, advise physicians on how to treat their 
patients with clinically unproven methods in order to opti-
mize sales of nutritional supplement products sold by the 
laboratory. While arguably it is the responsibility of the phy-
sician to implement or reject treatment advice, the whole 
concept of laboratory owners and employees with no first-
hand patient care training, experience, or medical licensure, 
telling doctors how to treat their patients with clinically 
unproven methods may be construed as the unlicensed prac-
tice of medicine by unqualified individuals. At the very least 
it is a potential recipe for disaster.16–18
It is not hard to find physicians and other caregivers who 
are advertising the sale of urinary monoamine assays under 
the “spot baseline urinary neurotransmitter testing marketing 
model”. Their numbers have grown in recent years. Some of 
the examples of Internet marketing of urinary monoamine 
assays under the “spot baseline urinary neurotransmitter 
testing marketing model” by physicians and other caregivers 
include the following assertions:
•	 “Neurotransmitter testing is now available to detect brain 
neurotransmitter imbalances”19
•	 “Neurotransmitter testing is used to detect imbalances in 
brain and body chemistry”20
•	 “We now have (urinary neurotransmitter) laboratory 
tests that can accurately measure neurotransmitter levels 
and greatly simplify the task of developing a proper 
supplement plan, eliminating much of the guesswork 
and trial and error. They are also affordable and non-
invasive in that they use a simple urine sample. A base-
line test is usually critical to understanding a person’s 
unique   patterns and designing the most appropriate 
supplement program”21International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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•	 “… approach is based on a baseline (urinary)   measurement 
of your neurotransmitter and/or hormone levels. The 
initial testing of your levels from a urine or saliva sample 
constitutes your baseline”22
•	 “Neurotransmitter testing to detect brain neurotransmitter 
imbalances! Testing helps to determine exactly which 
neurotransmitter levels are out of balance and helps to 
determine which therapies are needed for an individual-
ized treatment plan”23
•	 “For this to be most effective, it should include a special-
ized urinalysis test that provides a reliable means of 
measuring excretory values of neurotransmitters. The 
(name of company) neurotransmitter urinalysis panel can 
be utilized to establish baseline, therapeutic, and main-
tenance protocols”24
•	 “Neurotransmitters are naturally occurring chemicals 
within the brain that relay signals between the nerve cells 
and are required for proper brain and body function. The 
approach is based on a baseline (urinary) measurement 
of your neurotransmitter and/or hormone levels”.25
Laboratory marketing claims
This section discusses how the marketing model arrived at 
its current state, along with examples of the marketing claims 
made to fuel urinary monoamine testing. The marketing 
model is promoted primarily for disease states that have a 
high positive placebo effect. In many studies, attention deficit 
hyperactivity disorder and depression are associated with a 
positive placebo effect of 40%–50%.5,9 Almost half of the 
patients with these diseases improve significantly in 1 month 
while being treated with placebo. However, under the mar-
keting model, when this happens, those promoting the mar-
keting model take credit for all cases that have improved. 
Because almost half of the patients show significant improve-
ment within 1 month, there is little upon which to challenge 
the veracity of the laboratory claims of treatment efficacy 
for the average physician not aware of the placebo statistics. 
Indeed, physicians have said under questioning, “I like this 
approach; at least half of my patients get better in the first 
month”. This approach completely ignores the placebo effect 
while quietly exploiting it in the background for the market-
ing of urinary monoamine assays.5,9
Virtually any properly licensed laboratory can perform 
urinary monoamine assays. It is the clinical applications 
promoted for these urinary monoamine assays that differenti-
ate one laboratory from another. The following are direct 
quotes from urinary monoamine assay marketing under the 
urinary neurotransmitter marketing model.
A 2007 marketing paper noted, “Studies have   demonstrated 
intact neurotransmitter transport out of the CNS, into the 
periphery, via blood–brain barrier transporters. Renal filtra-
tion of neurotransmitters via specific transporters is well-
documented. Researchers have provided examples of urinary 
neurotransmitter measurements that correlate with CNS 
(central nervous system) tissue concentrations”.26
On September 22, 2010, a laboratory website27 promot-
ing and selling urinary monoamine assay under the spot 
baseline urinary neurotransmitter testing marketing model 
on the Internet noted that baseline testing is recommended 
with regard to urinary monoamine assays in marketing for 
all neurotransmitter-related conditions for several 
reasons:
•	 “First, it reveals imbalances that may be present in the 
nervous system, thereby establishing a quantitative need 
for intervention. Symptoms alone often do not provide 
the information needed to effectively target the underly-
ing neurotransmitter imbalances”
•	 “Next, baseline testing allows for more informed deci-
sions to be made regarding intervention selection”
•	 “With neurotransmitter data in hand, practitioners can 
choose products that target neurotransmitter imbalances”
•	 “Likewise, neurotransmitter testing shows which inter-
ventions may not be suitable for a particular individual, 
reducing the chance of unwanted side effects”
•	 “Finally, the baseline test provides an important reference 
point to monitor the effects of therapy. Retests can be 
compared to baseline data to evaluate progress made in 
the restoration process”
•	 “In addition to baseline testing, periodic retesting is used 
to indicate a need for change in a patient’s dosing 
regimen”.
The websites of other laboratories have posted the fol-
lowing on their web pages supporting sales of urinary mono-
amine assays under the spot baseline urinary neurotransmitter 
testing marketing model:
•	 “(Company name) line of formulas designed to address 
the communication system imbalances found through 
testing. TNT formulations may be used as anchor prod-
ucts during the initial therapeutic phase, following a 
baseline (urinary) test”28
•	 “For this to be most effective, it should include a special-
ized urinalysis test that provides a reliable means of 
measuring excretory values of neurotransmitters. From 
those findings an individualized protocol including trans-
dermal amino acid supplementation is devised to improve 
the quantity and ratios of neurotransmitters in the International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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brain. The first step is to identify baseline (urinary) 
  neurotransmitter levels”2
•	 “The optimal range is suggested for the interpretation of 
baseline (urinary neurotransmitter testing) values. If 
neurotransmitter values fall above or below the optimal 
range, your nervous system may be out of balance”29
•	 “In support of urinary neurotransmitter assessment, studies 
have demonstrated that intact neurotransmitter is trans-
ported from the CNS to the periphery, via specific BBB 
transporters, followed by renal filtration of neurotransmit-
ters with subsequent excretion in the urine”.30
Scientific issues
There is a highly polarized divergence between published 
peer-reviewed science and the “spot baseline urinary neu-
rotransmitter testing marketing model”. In this section we 
discuss the key points of this divergence. In order to enable 
the reader to sort out which claims from caregivers and labo-
ratories are correct, it is important to identify and discuss the 
scientific foundation the marketing model is resting on. The 
validity of the spot baseline urinary neurotransmitter testing 
marketing model used to promote sales of urinary monoamine 
assays rests on correct answers to the following questions. 
What is the permeability of the blood–brain barrier regarding 
the monoamines under normal conditions? Are significant 
amounts of monoamines found in the final urine synthesized 
by kidney structures under normal conditions? What is the 
level of reproducibility of urinary monoamine testing results 
from the same subject on a day-to-day basis?
Blood–brain barrier permeability
Some variations of “the marketing model” rest on claims that 
measurement of urinary monoamines has a direct relationship 
with the monoamine levels found in the brain. This gives 
rise to the concept “pee in a cup and we will determine the 
neurotransmitter levels of your brain model”.
Two specific considerations exist in the marketing model 
when claiming that monoamines cross the blood–brain 
  barrier. The first assumption is that monoamines found in 
the final urine contain monoamines that have been in the 
central nervous system. The second requirement is that the 
monoamines in the final urine are in constant equilibrium 
with the monoamines found in the central nervous system 
and peripheral nervous system. Embodied in the marketing 
model is the concept that monoamines must cross the blood–
brain barrier then come to equilibrium with the peripheral 
nervous system and final urine, leading to one large pool of 
monoamines in constant equilibrium throughout the body.
The idea that monoamines do not cross the blood–brain 
barrier under normal conditions has been widely accepted in 
science for over 60 years. This fact has been referenced 
heavily over time, as noted in the sampling of 104 references 
noted in support of the following four bullet points:
•	 “Serotonin does not cross the blood–brain barrier”5–7,31–69
•	 “Dopamine does not cross the blood–brain barrier”70–93
•	 “Norepinephrine does not cross the blood–brain 
barrier”94–107
•	 “Epinephrine does not cross the blood–brain barrier”.108–131
In order for claims made under the spot urinary neu-
rotransmitter testing marketing model to be valid, monoam-
ines must cross the blood–brain barrier. This is contrary to 
the over 100 references cited above. When those promoting 
the original laboratory marketing model, which is still pro-
moted by some today, became cognizant that these mono-
amines did not freely cross the blood–brain barrier, the model 
began to change. The new marketing argument asserts that 
transporters move monoamines across the blood–brain bar-
rier in amounts significant enough to affect equilibrium 
between the central nervous system, peripheral nervous 
system, and final urine. It continues to be asserted that mono-
amines in the final urine are composed of monoamines that 
have been in the central nervous system.30
A review of transporter physiology is in order. The mono-
amines are primarily transported by organic cation transport-
ers (OCT).132 It is recognized that the OCT of the liver, 
intestines,  kidneys,  and  brain  are  “identical  and 
homologous”.133 In 2010, the authors of this paper published 
the most recent refinement to the monoamine OCT model.6
Even if there were transporters that transported mono-
amines out of the brain to the peripheral nervous system, 
there would be no equilibrium or direct relationship, as 
asserted by the marketing model, between the central nervous 
system, peripheral nervous system, and final urine. The 
amounts of monoamines that are transported vary greatly 
over time. During transport, OCT affect monoamine gradi-
ents where the amount of monoamine on one side of the 
transporter is not the same as the amount on the other side 
of the transporter. In addition, monoamine concentrations 
on either side of the transporter rise and fall independent of 
each other. This leads to a situation where if transport did 
occur, the monoamines in the central nervous system are not 
in equilibrium and do not share a direct relationship with 
levels in the peripheral nervous system and final urine, as 
alleged by the marketing model.6
In the transporter version of the marketing model, the 
laboratories involved continue to assert that urinary International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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  monoamine levels correlate with monoamines in the central 
nervous system and are a measurement of monoamines that 
have been in the central nervous system.7,19–30 A published 
discussion of blood–brain barrier transport under one of the 
current marketing models written by the staff of a laboratory 
selling under the marketing model appeared in a 2010 review 
article (ie, no original research was reported) published by a 
psychology journal that had decided it had the expertise to 
publish on peer-reviewed issues relating to monoamine renal 
physiology and blood–brain barrier physiology.30 Figure 1 
accompanying that review is a reproduction from Ohtsuki.134 
The article claimed that both illustrations represent transport 
of monoamines across the blood–brain barrier. Close 
examination of the reference shows that the assertions of 
Ohtsuki are contrary to the psychology review article in 
noting that there is no known mechanism for these 
monoamines that transports them across the blood–brain 
barrier. The only thing that the figures from these two articles 
illustrate is how the monoamines are transported into the 
endothelial cells of the blood–brain barrier where they affect 
regulation and that the monoamines are not transported across 
the blood–brain barrier.30,134
There is no peer-reviewed published research that supports 
the marketing model versions which expound that, under 
normal conditions, monoamines cross the blood–brain barrier 
and are in equilibrium with the peripheral nervous system, 
urinary monoamine assays are of monoamines that have been 
in the brain, and assays of monoamines found in the final 
urine have a direct relationship with levels found in the brain. 
There is no scientific support for any of these propositions.
Source of urinary monoamines
The second major issue reviewed is “the source of synthesis 
of monoamines found in the urine under normal condi-
tions”. The selling of urinary monoamine assays under the 
“the marketing model” has made no scientific room for the 
possibility that a significant source of synthesis of the 
monoamines found in the final urine is from sources other 
than the peripheral or central nervous systems. The market-
ing model claim is that urinary monoamines found in the 
final urine are monoamines filtered at the glomerulus, and 
measurement of monoamines in the final urine is a direct 
assay of the monoamines of the peripheral and/or central 
nervous systems. The marketing model fails to account for 
known scientific facts that are contrary to these 
assertions.30
Science notes that significant amounts of monoamines 
found in the urine, under normal conditions, have never been 
in the central and/or peripheral nervous systems. The final 
urine, under normal conditions, is composed of significant 
amounts of monoamines synthesized by structures found in 
the kidneys. The following referenced statements support 
this set of facts:
•	 “Most of the serotonin or dopamine found in the urine is 
synthesized in the kidney. Therefore, the excreted 
neurotransmitters must be synthesized in the kidneys and 
escape reabsorption into the blood in order to be excreted 
in the urine”14
•	 “These findings provide further evidence that the increase 
in urine serotonin after administration of both serotonin 
precursors (5-HTP; glu-5-HTP) is largely due to serotonin 
synthesized within the kidney”135
•	 “… free urine serotonin reflects actual biosynthesis by 
the kidney”136
•	 “These results are consistent with the intrarenal formation 
of serotonin by renal decarboxylase with attendant altera-
tions in renal hemodynamics and salt and water 
excretion”137
•	 “Dopamine and serotonin in the urine are believed to 
reflect mainly the tubular decarboxylation of filtered or 
circulating L-dopa and L-5-HTP, respectively”138
•	 “Intrarenal dopamine (3,4-dihydroxyphenethylamine; DA) 
and serotonin (5-hydroxytryptamine; 5-HT) are   synthesized 
abundantly by renal proximal tubular cells from L-3,4-
dihydroxyphenylalanine and 5-  hydroxy-L-tryptophan, 
respectively”139
•	 “These data indicate that urinary free dopamine is mainly 
derived from plasma dopa, which is converted by dopa 
decarboxylase in the kidney”140
•	 “Urinary dopamine excretion was not diminished by 
sympathectomy, was increased by L-dopa (but not 
tyrosine or dopamine 4-Osulphate) in the perfusate and 
was virtually abolished by prior treatment with the dopa 
decarboxylase inhibitor, carbidopa. These results confirm 
the importance of renal extraneuronal dopamine produc-
tion, from circulating L-dopa, as a contributor to urinary 
dopamine excretion”141
•	 “The data indicates that urinary free dopamine in a high 
sodium diet is mainly derived from the renal tubular 
cells”142
•	 “Plasma dopa is the main source of urinary dopamine”143
•	 “All of the components of a complete dopamine system 
are present within the kidney”144
•	 “It is concluded that (urinary) dopamine and serotonin 
are accumulated and likely formed within proximal 
  convoluted tubular cells”145International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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•	 “... (urinary) dopamine is phosphaturic and is synthesized 
by kidney proximal tubule”146
•	 “... urinary norepinephrine is not solely derived from 
plasma by glomerular filtration but also arises from an 
unidentified renal source”147
•	 “… the renal nerves were the main sites of the (urinary) 
norepinephrine synthesis”148
•	 “Perfusion of L-dopa and free dopamine led to the 
  generation of norepinephrine in the kidney. This synthesis 
was abolished when the kidney was denervated, 
  suggesting that the renal nerves were the main sites of 
the (urinary) norepinephrine synthesis”148
•	 “Several recent studies have demonstrated that dopamine 
can be generated from L-dopa in the isolated perfused 
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Figure 1 Serotonin, dopamine, norepinephrine, and epinephrine are transported across the abluminal membrane surface of the blood–brain barrier into the endothelial cells 
where they affect regulatory function. They do not cross the blood–brain barrier since they do not cross the luminal membrane.
Reprinted from Neuroscience & Biobehavioral Reviews, vol 35, Issue 3, Marc et al, Neurotransmitters excreted in the urine as biomarkers of nervous system activity: validity 
and clinical applicability, p 635–644, Copyright 2011, with permission from elsevier.
Abbreviations: eAAT, excitatory amino acid transporter; GABA, γ-aminobutyric acid; GAT2/BGT-1, GABA/betaine transporter; HA, histamine; NeT, norepinephrine 
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rat kidney, and those findings led to the conclusion that 
most of the urinary dopamine could be derived from 
circulating L-dopa (in the kidneys)”148
•	 “Recent studies from our laboratory have suggested that 
urinary NE (norepinephrine) may be derived, in part, from 
intrarenal sources in man”149
•	 “We have previously reported that in standing humans a 
significant portion of urinary norepinephrine is derived 
from processes other than glomerular filtration”149
•	 “Net production was observed for NE (norepinephrine), 
DA (dopamine), and NM (normetanephrine) in the renal 
metabolic compartment, suggesting that a portion of these 
compounds excreted in the urine may result from intra-
renal synthesis or metabolism of these materials”149
•	 “… urinary epinephrine may not simply be filtered from 
the bloodstream” and “urinary epinephrine was derived 
from the kidney”150
•	 “We conclude that appreciable portions of renal and 
urinary epinephrine are synthesized in the kidney by an 
enzyme distinct from PNMT”.151
In reviewing the validity of the “spot baseline urinary 
neurotransmitter testing marketing model” it is important to 
determine what is being assayed and where it came from. 
The first assertion of the model claims that it is urinary 
neurotransmitters that are being assayed. Considering the 
neurohormonal, regulatory, paracrine, and autocrine func-
tions of monoamines, the monoamine population found in 
the urine has not exclusively functioned as neurotransmitters. 
This marketing model hinges on claims that the final urine 
is composed of monoamines that have functioned only as 
neurotransmitters, which have crossed the blood–brain bar-
rier, and have been simply filtered at the glomerulus, and 
then excreted directly into the final urine. Therefore, the 
marketing model, has assumed that there is constant equi-
librium between the monoamines of the central and peripheral 
nervous systems and the monoamines found in the final urine 
which have allegedly only functioned as neurotransmitters. 
This marketing model is simply not valid. There is no direct 
relationship between monoamines in the final urine and 
monoamines in the peripheral or central nervous systems, 
and under normal conditions, significant amounts of 
  monoamines found in the final urine have not been in the 
peripheral or central nervous systems, but have been newly 
synthesized by structures in the kidneys.
Day-to-day reproducibility of assays
The reproducibility of testing techniques in the laboratory, as 
commonly addressed by precision and accuracy studies, is 
not what is being discussed here. It is the reproducibility of 
urinary monoamine assay results obtained from the same 
subject from one day to the next that is under discussion. It 
would appear that none of the laboratories selling urinary 
monoamine testing under this marketing model bothered to 
verify the day-to-day reproducibility of testing in the same 
subject. The authors of this paper published multiple original 
research papers where the topic was “matched-pairs t-test” 
analysis of baseline monoamine assays performed on different 
days from the same subject. Each matched pair was made up 
of a urine sample obtained from a subject on one day (test 1) 
paired with a urine sample from the same subject on a different 
day (test 2). These test 1 and test 2 matched pairs were then 
grouped and analyzed using the “matched-pairs t-test”. It was 
found that the urinary level of all four monoamines (serotonin, 
dopamine, norepinephrine, and epinephrine) between test 1 
and test 2 for the group differed significantly from day to day 
(P , 0.05). The amount of each monoamine found in test 1 
and test 2 urine samples was not consistent and reproducible 
on a day-to-day basis in the same individual.7,10 The following 
statement illustrates the impact of this finding: “It is asserted 
that if one hundred baseline urinary monoamine assays from 
the same subject were obtained on one hundred different days, 
one hundred different laboratory values would be reported. 
In the process, no firm reproducible laboratory data from one 
day to another day would be generated and no reliable clinical 
decision making could occur using this type of data”.7,10 These 
findings invalidate the ability to use “baseline monoamine 
assays” for anything more than a coarse screening tool, under 
the only clinically proven applications known, for monoamine 
hyperexcreting tumors,7,10 which is something we are not 
discussing in this paper.
Unproven science of biomarkers
The alleged scientific foundation of the marketing model 
continues to change. The marketing model still continues to 
assert that all of the urinary monoamines found in the final 
urine under normal conditions have been in the peripheral 
and central nervous systems, despite the overwhelming 
  peer-reviewed published research evidence to the contrary. 
The marketing model now asserts that urinary monoamines 
can be used as biomarkers of common diseases, such as 
attention deficit hyperactivity disorder and depression, 
although these claims are clinically unproven with no pub-
lished original research that would support or define treatment 
of the individual patient in clinic. The only published original 
research on the topic discredits the biomarker approach for 
several of the reasons already discussed in this paper, not the International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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least of which is the lack of day-to-day consistency of test 
results in the same subject.30
The business model for the marketing of urinary mono-
amine assays as biomarkers of disease has certainly arrived. 
The most extensive writing on the topic is a 2010 literature 
review found in a psychology journal and containing no 
original research.30 Contrary to the claims of the biomarker 
marketing model cited,30 the final urine being assayed 
contains significant amounts of urinary monoamines 
synthesized by the kidneys. The actual monoamine levels 
found in the final urine when corrected for specific gravity 
considerations by use of the monoamine to creatinine ratio 
which compensates for dilution of the urine, is an assay of 
the forces within the kidneys that impact the monoamines 
between synthesis and the final urine. The OCTN2 
transporters of the apical surface and the OCT2 transporters 
of the basolateral surfaces of the proximal convoluted renal 
tubule cells have a major impact on monoamine concentrations 
found in the final urine.13 The marketing model is silent on 
this interaction.
The most recent review of urinary biomarker applications 
had numerous references citing group results of urinary 
monoamine trends. The authors then made the jump, without 
proper studies in place, to asserting that these group results 
are valid for use in treatment of individual patients in the 
clinical setting.30 Group study results cannot be used or 
equated to treatment parameters in an individual. Even if a 
group trend was found for a specific disease, the day-to-day 
significant changes in urinary monoamine assays from the 
same individual would invalidate the clinical applications of 
the group trend finding.7,10
The question is raised, “What is the possible impact to 
the medical community of laboratories selling clinically 
unproven urinary biomarker tests?” One of the references 
cited in the bibliography of the 2010 biomarker review 
paper30 notes the following:
“Perhaps most worrisome is the problem of premature 
clinical application (of biomarkers), both because of the risk 
for harm to patients (misdirected in treatment decisions) and 
for the cynicism about biomarkers in general this engenders; 
still, the need for useful biomarkers is so great that sometimes 
enthusiasm and optimism may overtake consideration of 
results from carefully conducted controlled clinical trials. To 
paraphrase the film Jerry Maguire, ‘show me the data!’ must 
be the watchword if clinicians are to make prudent choices 
for their patients”.152
The authors of this paper assert that the statement imme-
diately above, in citing “premature clinical applications” of 
biomarker testing,152 are discussing the exact problem associ-
ated with the urinary monoamine marketing model of bio-
markers at this time. Careful review of the references cited 
revealed no definitive clinical trials or support regarding use 
of spot baseline urinary neurotransmitter testing in biomarker 
applications for treatment of individuals in the clinical set-
ting. The statement referenced above is correct in that pre-
mature use of an unproven biomarker application can risk 
causing harm to the patient. Examples of the harm supported 
under the statement include152 but are not limited to:
•	 A diagnosis of a false normal state when disease exists
•	 Misdiagnosis of disease states
•	 Medical treatment decisions that make the disease state 
worse
•	 Initiation of unnecessary treatment
•	 Delay in implementing available beneficial treatment
•	 False hope given where no hope exists, leading to distress 
when this is realized
•	 Interference with the doctor–patient relationship when 
expected results promoted by the laboratory do not turn 
out as advertised due to unrealistic expectations of care.
Conclusion
The “spot baseline urinary neurotransmitter testing marketing 
model” used to promote sales of urinary monoamine assays 
is not valid and has no scientific foundation. For the claims 
of the marketing model to be valid, monoamines would need 
to cross the blood–brain barrier and be in constant equilib-
rium with the peripheral nervous system and final urine. As 
demonstrated by at least 100 citations, these monoamines do 
not cross the blood–brain barrier. While one version of the 
marketing model seems to recognize this and asserts that the 
monoamines are transported out of the central nervous sys-
tem, the very literature cited in making these transporter 
assertions specifically illustrates that monoamines are not 
transported out of the central nervous system to the peripheral 
nervous system. For the marketing model to be valid, mono-
amines found in the final urine need to be composed primarily 
of the monoamines from the peripheral system that are merely 
filtered and placed in the final urine as claimed. A significant 
amount of monoamines found in the final urine are synthe-
sized by the kidneys. These monoamines perform other major 
functions in the body. Therefore, identifying and calling these 
monoamine assays of the final urine, “neurotransmitter test-
ing” is not appropriate.
For the marketing model to be valid, urinary monoamine 
assays obtained from the same subject need to be consistent 
from one day to the next (P . 0.05 on the “matched-pairs International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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t-test” using paired samples from the same subject obtained 
on different days). Previous published literature indicates 
that this is not the case; urinary monoamines differ signifi-
cantly from day to day in the same subject.
The bottom line is that the “spot baseline urinary 
neurotransmitter testing marketing model” used to sell uri-
nary monoamine assays has not been clinically proven. The 
original scientific research supporting the model, if it exists, 
cannot be found in published science. It is postulated that 
after 10 years of using this marketing model to sell urinary 
monoamine assays it would be helpful if the first original 
research scientific peer-reviewed paper outlining the founda-
tion of the model would be formally written in order to 
subject it to appropriate peer review.
It is the goal of this writing to spark interest and dialog 
on the validity of the “spot baseline urinary neurotransmitter 
testing marketing model” used in support of urinary mono-
amine assay sales. We hope that those using this marketing 
model directly or indirectly in patient care will come forth 
and enter into meaningful dialog. It is suggested that those 
promoting this marketing model publish their original 
research findings in order to facilitate a proper scientific 
dialog on the topics of monoamine renal physiology and 
blood–brain barrier permeability in relation to marketing 
claims.
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